Tag Archives: Medivir

April, 2017

7 April
Medivir Announces Positive Results from its Mid-Stage Lymphoma Study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces the completion of the phase II clinical study of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in patients with early stage CTCL. The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to …
Share

2 November
Medivir Sells Pharmaceutical Company BioPhausia to Karo Pharma

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has entered into an agreement with Karo Pharma AB regarding the sale of Medivir’s subsidiary BioPhausia AB (Nordic Brands) to Karo Pharma. The purchase price will be SEK 908 million on a cash and debt free basis, …
Share

13 April
Medivir and Cancer Research Technology Team Up to Develop A New Class of Cancer Drugs

Swedish biotech Medivir and Cancer Research Technology (CRT) are teaming up to develop a new class of drugs that have shown promise in various cancer types. Medivir and CRT, Cancer Research UK’s commercialization and development arm, said that they have partnered to develop a new class of drugs targeting ADAM8, …
Share